78 completed, 6 withdrawn, 3 recruiting, 2 unknown. 40 Phase 3, 24 Phase 4, 13 Phase 2, 8 Phase 1, 5 Not applicable.
Follow fluticasone furoate: new trials by email Literature Review of fluticasone furoate trials Research Report on fluticasone furoate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma Fluticasone furoate and vilanterol inhalation powder, Breo Ellipta, Placebo - Respiratory | Phase 3 | Withdrawn | Sandoz | 2026-04-21 | 2026-05-12 | |
| VENTURI (VENTilation Using Respiratory Imaging) Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder - Asthma | Phase 2 | Recruiting | University of Alabama at Birmingham | 20 | 2026-03-15 | 2026-04-13 |
| The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis Quercetin, Apple Extract, Loratadine 10 Mg - Rhinitis, Allergic, Perennial | Not applicable | Completed | Universitas Sebelas Maret | 40 | 2025-04-01 | 2026-02-02 |
| Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study Budesonide/Glycopyrronium/Formoterol (BGF), Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) - COPD, Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Completed | Thammasat University | 22 | 2025-04-01 | 2026-02-02 |
| Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists - Asthma | Phase 4 | Active not recruiting | GlaxoSmithKline | 1358 | 2024-04-16 | 2026-10-06 |
| U-LABA/ICS Effects on Exercise Performance, Vilanterol Vilanterol and Fluticasone Furoate (low dose), Vilanterol and Fluticasone Furoate (high dose), Placebo - Exercise Performance | Not applicable | Recruiting | Morten Hostrup, PhD | 30 | 2023-10-03 | 2025-04-10 |
| Role of Lung Function for Exercise Capacity in Well-trained Individuals Vilanterol and Fluticasone Furoate, Indacaterol and Mometasone Furoate, Placebo - Exercise Performance | Not applicable | Recruiting | Morten Hostrup, PhD | 60 | 2023-10-03 | 2025-04-09 |
| Medical vs Surgical Treatment in OSA Among Children Montelukast, Fluticasone Furoate - To Evaluate PSQ as Clinical Tool in the Decision Between Medical and Surgical Treatment for Adenotonsillar Hypertrophy, To Determine Clinical Response to Montelukast or Nasal Steroids Based on PSQ Results | Phase 4 | Unknown | Assaf-Harofeh Medical Center | 90 | 2022-11-15 | 2022-12-15 |
| Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps. Montelukast, Prednisolone, Fluticasone Furoate - Montelukast, Chronic Rhinosinusitis With Nasal Polyps | Phase 1 / Phase 2 | Unknown | Assiut University | 60 | 2022-01-01 | 2022-03-18 |
| A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD) Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg) - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 9117 | 2021-12-17 | 2023-10-19 | |
| TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg, Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg - COPD | Phase 4 | Withdrawn | Chiesi Farmaceutici S.p.A. | 2021-10-04 | 2022-02-03 | |
| ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone) Fluticasone, Placebo - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 1407 | 2021-08-06 | 2023-06-18 |
| ACTIV-6: COVID-19 Study of Repurposed Medications Ivermectin, Fluvoxamine, Fluticasone - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 10956 | 2021-06-08 | 2025-11-17 |
| Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists, Fluticasone furoate/umeclidinium/vilanterol - Pulmonary Disease, Chronic Obstructive | Phase 4 | Withdrawn | GlaxoSmithKline | 2019-06-27 | 2020-04-22 | |
| Effect of Fluticasone Furoate/Vilanterol on EIA in Adolescents Fluticasone furoate (FF)/Vilanterol (VI), Salbutamol - Asthma in Children | Phase 4 | Completed | Rambam Health Care Campus | 92 | 2018-12-01 | 2021-02-11 |
| Effect of Fluticasone Furoate on Methacholine Challenge Fluticasone furoate, Matching placebo - Asthma | Phase 4 | Completed | University of Saskatchewan | 14 | 2018-10-30 | 2019-12-10 |
| The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma Fluticasone Furoate/Vilanterol, Fluticasone Furoate, Salbutamol/Albuterol - Asthma | Phase 4 | Withdrawn | GlaxoSmithKline | 2018-03-07 | 2018-01-29 | |
| Effect of Vilanterol on Methacholine Challenge Results Vilanterol and Fluticasone Furoate, Fluticasone Furoate, Placebos - Asthma | Phase 4 | Completed | University of Saskatchewan | 17 | 2017-10-13 | 2018-10-11 |
| Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes. Fluticasone Furoate/Vilanterol 100/25 mcgs, Umeclidinium/Vilanterol 62.5/25 mcgs - COPD | Phase 4 | Completed | National Institute of Respiratory Diseases, Mexico | 133 | 2017-09-19 | 2022-04-22 |
| Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year Fluticasone furoate, Placebo, Montelukast - Asthma | Phase 4 | Completed | GlaxoSmithKline | 477 | 2017-07-10 | 2024-01-17 |
Showing 20 of 91. Sign in to see all of them.
Asthma (41) · Pulmonary Disease, Chronic Obstructive (24) · Rhinitis, Allergic, Seasonal (9) · Rhinitis, Allergic (8) · Rhinitis, Allergic, Perennial (6) · COVID-19 (2) · Cardiovascular Diseases (2) · Rhinitis (2) · Asthma, Exercise-Induced (1) · Motor Activity (1) · Nasal Polyps (1) · Respiratory Hypersensitivity (1)
GlaxoSmithKline (65) · University of Chicago (5) · Morten Hostrup, PhD (2) · Sandoz (2) · Susanna Naggie, MD (2) · University of Saskatchewan (2) · Assaf-Harofeh Medical Center (1) · Assiut University (1) · Boehringer Ingelheim (1) · Chiesi Farmaceutici S.p.A. (1) · Johns Hopkins University (1) · Maastricht University Medical Center (1) · Nanhua University (1) · National Institute of Respiratory Diseases, Mexico (1) · Rambam Health Care Campus (1)
United States (46) · Germany (25) · Russia (17) · Poland (16) · Romania (14) · Japan (13) · Ukraine (11) · Argentina (10) · Canada (10) · Mexico (10) · Australia (9) · United Kingdom (9) · Netherlands (8) · Philippines (8) · South Korea (8)
Adrian Hernandez, MD (2) · Morten Hostrup, PhD (2) · Robert M Naclerio, MD (2) · Susanna Naggie, MD (2) · Brian Lipworth, MD (1) · Catherine Jackson, MD (1) · Chun-Chih Lin, Professor (1) · Don Cockcroft, MD (1) · Fuad M Baroody, MD (1) · James Chalmers, MBChB, MRCP (1) · Lea Bentur, MD (1) · Narongkorn Saiphoklang, MD (1) · Robert Naclerio, MD (1)
PMID 27881132, PMID 36472162, PMID 24966061, PMID 26704701, PMID 24314123, PMID 24998880, PMID 32771685, PMID 37012070, PMID 10380774, PMID 12773705, PMID 1532808, PMID 1593914, PMID 15992574, PMID 16088266, PMID 16606412, PMID 16960636, PMID 17561703, PMID 17968683, PMID 18002246, PMID 19428097, PMID 19602651, PMID 19885944, PMID 19964539, PMID 20816182, PMID 21377716, PMID 22430337, PMID 22796247, PMID 22934336, PMID 23018908, PMID 23406588, PMID 23406601, PMID 23430080, PMID 23710948, PMID 23846316, PMID 24093504, PMID 24107462, PMID 24114969, PMID 24136330, PMID 24253831, PMID 24535140, PMID 24589166, PMID 24603195, PMID 24991883, PMID 25007865, PMID 25058845, PMID 25108545, PMID 25180727, PMID 25213048, PMID 25830381, PMID 26291137
2016 (3), U24TR001608 (2), 2017 (1), 2019 (1)